
-
Macron, Putin discuss Iran, Ukraine in first talks since 2022
-
French league launches own channel to broadcast Ligue 1
-
Man City left to reflect on Club World Cup exit as tournament opens up
-
Shock study: Mild electric stimulation boosts math ability
-
Europe swelters as surprise early summer heatwave spreads
-
Third seed Zverev stunned at Wimbledon
-
Israel expands Gaza campaign ahead of Netanyahu's US visit
-
Gaza mourns those killed in Israeli strike on seafront cafe
-
Rubio hails end of USAID as Bush, Obama deplore cost in lives
-
Berlusconi family sell Monza football club to US investment fund
-
UN aid meeting seeks end to Global South debt crisis
-
Trump ramps up Musk feud with deportation threat
-
French paparazzi boss handed 18-month suspended sentence for blackmail
-
Gilgeous-Alexander agrees record $285 mln extension: reports
-
Tearful former champion Kvitova loses on Wimbledon farewell
-
IMF urges Swiss to strengthen bank resilience
-
Sri Lanka eye top-three spot in ODI rankings
-
Trump hails new 'Alligator Alcatraz' migrant detention center
-
US Senate approves divisive Trump spending bill
-
Krejcikova toughs it out in Wimbledon opener, Sinner cruises
-
UK govt braces for crunch welfare reforms vote amid major rebellion
-
Shifting to Asia, Rubio meets Quad and talks minerals
-
Stocks diverge while tracking US trade deal prospects
-
Bruce Lee Club closes archive doors citing operating costs
-
Trump ramps up Musk feud with deportation, DOGE threats
-
BTS announces comeback for spring 2026
-
Beating England without Bumrah 'not impossible' for India captain Gill
-
Krejcikova battles back against rising star Eala to win Wimbledon opener
-
US Republicans close in on make-or-break Trump mega-bill vote
-
Arsenal sign goalkeeper Kepa from Chelsea
-
Olympic champion Zheng knocked out of Wimbledon
-
Line judges missed at Wimbledon as AI takes their jobs
-
Tshituka to make Test debut as Springboks change five
-
'Remember Charlie Hebdo!' Protesters seethe at Istanbul magazine
-
Top seed Sinner eases into Wimbledon second round
-
Stocks retreat as profit-taking follows Wall Street records
-
Israel expands campaign in Gaza ahead of Netanyahu's US visit
-
Barcelona's Ansu Fati aims to kick-start career in Monaco
-
Bordeaux-Begles drawn with Northampton in Champions Cup final repeat
-
Sean Combs trial: jurors seek verdict for a second day
-
Trump says will 'take a look' at deporting Musk
-
Greece starts charging tourist tax on cruises
-
Trump heads for 'Alligator Alcatraz' migrant detention center
-
US Senate push to pass Trump's unpopular spending bill enters second day
-
England captain Stokes relishing Pant battle in India series
-
Ukraine hits Russian city deep behind front line, leaves three dead
-
Hinault backs 'complete rider' Pogacar for Tour de France glory
-
Third seed Pegula suffers shock Wimbledon exit
-
Stocks struggle tracking US trade deal prospects
-
Djokovic launches Grand Slam history bid at Wimbledon

New Horizon Medical Solutions Adds AmchoPlast(TM) to its Industry-Best Product Portfolio
Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing Patient Care
LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care innovation, today announced the launch and addition of AmchoPlast™ to its product portfolio. AmchoPlast is a premium amniotic‑chorionic membrane product designed to elevate outcomes across surgical and chronic wound indications.
"AmchoPlast strengthens our pipeline of compliant, performance-driven biologics that align with modern wound care protocols," said Will Hall, CEO, New Horizon Medical Solutions. "This launch reflects our commitment to regenerative medicine, practice optimization, and elevating standards of care."
Delivering superior benefits and practice optimization
Engineered with amniotic‑chorionic tissue, AmchoPlast serves as a natural biologic scaffold and barrier, supporting advanced wound care management and regenerative tissue growth.
Rich in growth factors and cytokines, it enhances angiogenesis, reduces inflammation, and promotes cellular proliferation and differentiation.
Biocompatible and non-immunogenic, the membrane is safe for a diverse patient population and a wide range of wound types.
With anti-inflammatory and anti-fibrotic activity, AmchoPlast helps reduce scarring, minimize adhesions, and accelerates epithelialization.
Designed for clinical workflow and reimbursement ease
Supplied in a sterile, ready-to-use format, AmchoPlast cuts procedural prep time and minimizes infection risk.
Shelf-stable at room temperature, it supports versatile storage for hospitals, clinics, or mobile settings.
Flexible, easy-to-handle, and available in multiple sizes, it facilitates precise application and reduces product wastage.
Supported by HCPCS‑compliant Q codes, AmchoPlast streamlines billing and reimbursement in line with CMS and payer requirements.
"The addition of AmchoPlast cements our portfolio as the most complete in the biologics space," said D. Christopher Keil, SVP, strategy & corporate development. "We now offer providers and partners the broadest range of choices when selecting regenerative solutions from New Horizon."
About AmchoPlast™
AmchoPlast, from Cellution Biologics, combines the regenerative power of amniotic and chorionic tissues in a dual-layer membrane. Intended for surgical reconstruction, chronic wounds (including diabetic foot ulcers and pressure injuries), burns, tendon and nerve repair, the product supports homologous use in clinical application, wound care, and optimized patient outcomes. For more information on the product, visit nhmedical.com/products/amchoplast or contact New Horizon Medical Solutions directly at 702-960-2913.
About New Horizon Medical Solutions
New Horizon Medical Solutions is at the forefront of biologic innovation and practice optimization. The company develops regenerative tissue products supported by reimbursement expertise and operational efficiency, empowering providers to improve patient outcomes while maintaining compliance. www.nhmedical.com
--
Media Contact
Julian Rogers, Director of Corporate Marketing
New Horizon Medical Solutions
[email protected]
702-971‑1806
SOURCE: New Horizon Medical Solutions
View the original press release on ACCESS Newswire
A.Jones--AMWN